Premium
Ranking of the antipsoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing—skin‐thickness, blood‐flow and colour measurements compared to clinical assessments
Author(s) -
BROBYJOHANSEN U.,
KARLSMARK T.,
PETERSEN L.J.,
SERUP J.
Publication year - 1990
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1990.tb02109.x
Subject(s) - medicine , dermatology , ranking (information retrieval) , blood flow , computer science , information retrieval
Summary In 10 patients with chronic plaque type psoriasis one or two plaques affected equally with psoriasis were chosen for study. Five punched out rings of a hydrocolloid dressing were applied to the psoriasis plaque(s). In each circular test area 20 mg of one of the following creams was applied: base, 1% hydrocortisone (DAK), 0·1% triamcinolone acetonide (Kenalogue ® ), 0·1%, betamethasone‐17‐valerate cream (Betnovate ® ), and 0·05% clobetasol proprionate cream (Dermovate ® ). The areas were occluded with a thin Him of transparent hydrocolloid dressing (Comfeel ® P Transparent Dressing), for 1 week. Non‐invasive measurements (ultrasound skin thickness, laser‐Doppler flowmetry, colorimetry) were performed before and after treatment. Therapeutic response was evaluated blindly by clinical score. The measurements showed a decline in blood How, a decrease in skin thickness, and normalization of colour approaching that of normal skin, the more potent the corticosteroid used. The clinical scores showed the same: the more potent a corticosteroid used, the closer to the score of normal skin. Data on variability and applications of the methods are presented. The study concludes that potent corticosteroids occluded with a hydrocolloid dressing can clear psoriasis in 1 week. Short‐course corticosteroid therapy appears harmless and relevant for clinical dermatology.